Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.088
Sell
RSI(14)
36.321
Neutral
STOCH(KDJ)(9,3,3)
32.871
Sell
ATR(14)
0.615
High Vlolatility
CCI(14)
-185.159
Sell
Williams %R
89.529
Oversold
TRIX(12,20)
0.009
Sell
StochRSI(14)
0.000
Sell
Search
Keros Therapeutics Inc
KROSAdd to Watchlist
10.500USD
-0.490-4.46%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
207.81MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Keros Therapeutics Inc
Currency: USD Updated: 2026-05-15Key Insights
Keros Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 53 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 21.20.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Keros Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Keros Therapeutics Inc Highlights
StrengthsRisks
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 161529.80% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is -4.15, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 22.62M shares, decreasing 59.03% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 61.93K shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
21.200
Target Price
+92.90%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Keros Therapeutics Inc is 6.52, ranking 232 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 367.00K, representing a year-over-year decrease of 99.83%, while its net profit experienced a year-over-year decrease of 115.97%.
Score
Financials
9.69
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.94
Operational Efficiency
2.72
Growth Potential
3.92
Shareholder Returns
8.31
Keros Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Keros Therapeutics Inc is 7.77, ranking 76 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.15, which is -1182.20% below the recent high of 44.91 and -2574.43% above the recent low of -110.99.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 53/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Keros Therapeutics Inc is 7.56, ranking 288 out of 382 in the Biotechnology & Medical Research industry. The average price target is 22.50, with a high of 35.00 and a low of 16.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
21.200
Target Price
+92.90%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Keros Therapeutics Inc
KROS
8
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Keros Therapeutics Inc is 6.02, ranking 290 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 11.71 and the support level at 9.80, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
11.428
Sell
MA10
11.611
Sell
MA20
11.484
Sell
MA50
11.428
Sell
MA100
14.599
Sell
MA200
15.427
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Keros Therapeutics Inc is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 114.30%, representing a quarter-over-quarter increase of 16.94%. The largest institutional shareholder is James Simons, holding a total of 453.48K shares, representing 2.29% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Keros Therapeutics Inc is 5.98, ranking 30 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.95. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.93
VaR
+5.18%
240-Day Maximum Drawdown
+51.92%
240-Day Volatility
+47.63%
Return
Best Daily Return
60 days
+5.89%
120 days
+11.99%
5 years
+32.45%
Worst Daily Return
60 days
-14.96%
120 days
-14.96%
5 years
-73.15%
Sharpe Ratio
60 days
-2.86
120 days
-1.58
5 years
+0.07
Risk Assessment
Maximum Drawdown
240 days
+51.92%
3 years
+86.45%
5 years
+86.45%
Return-to-Drawdown Ratio
240 days
-0.55
3 years
-0.28
5 years
-0.16
Skewness
240 days
-0.37
3 years
-6.69
5 years
-3.52
Volatility
Realised Volatility
240 days
+47.63%
5 years
+87.09%
Standardised True Range
240 days
+6.08%
5 years
+20.32%
Downside Risk-Adjusted Return
120 days
-213.21%
240 days
-213.21%
Maximum Daily Upside Volatility
60 days
+34.63%
Maximum Daily Downside Volatility
60 days
+51.19%
Liquidity
Average Turnover Rate
60 days
+1.06%
120 days
+1.23%
5 years
--
Turnover Deviation
20 days
-56.28%
60 days
-41.74%
120 days
-32.26%
Peer Comparison
Biotechnology & Medical Research
Keros Therapeutics Inc
KROS
7.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
